TrialAdvances in therapy2025

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.

Guillermo Garcia-Manero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.